HER2-targeted therapies improve outcomes by shutting down growth signaling to cancer cells, targeted delivery of chemotherapy, or blocking intracellular signaling – all leveraging the HER2 receptor to better control metastatic breast cancer.
HER2-targeted therapies improve outcomes by shutting down growth signaling to cancer cells, targeted delivery of chemotherapy, or blocking intracellular signaling – all leveraging the HER2 receptor to better control metastatic breast cancer.
